SINGULAR FOCUS. UNMATCHED DELIVERY.
SINGULAR FOCUS. UNMATCHED DELIVERY.
The clinical research services partner built exclusively for hematologic malignancies and solid tumors, from Phase II through Phase IV.
The clinical research services partner built exclusively for hematologic malignancies and solid tumors, from Phase II through Phase IV.
PHASE II-IV
PHASE II-IV
SOLID TUMORS
SOLID TUMORS
HEMATOLOGIC MALIGNANCIES
HEMATOLOGIC MALIGNANCIES
CELL & GENE THERAPY
CELL & GENE THERAPY
ADAPTIVE TRIAL DESIGNS
ADAPTIVE TRIAL DESIGNS
SINGULAR FOCUS. UNMATCHED DELIVERY.
The clinical research services partner built exclusively for hematologic malignancies and solid tumors, from Phase II through Phase IV.
PHASE II-IV
SOLID TUMORS
HEMATOLOGIC MALIGNANCIES
CELL & GENE THERAPY
ADAPTIVE TRIAL DESIGNS
KARAMATA™ is a clinical research service provider built around hematology and oncology. Four capability categories are reserved for that field; Clinical Research Finance and Regulatory Disclosure support programs across therapeutic areas. All six operate as one accountable system inside client-controlled environments, with scope, ownership, and decision boundaries visible from the start.
KARAMATA™ is a clinical research service provider built around hematology and oncology. Four capability categories are reserved for that field; Clinical Research Finance and Regulatory Disclosure support programs across therapeutic areas. All six operate as one accountable system inside client-controlled environments, with scope, ownership, and decision boundaries visible from the start.
KARAMATA™ is a clinical research service provider built around hematology and oncology. Four capability categories are reserved for that field; Clinical Research Finance and Regulatory Disclosure support programs across therapeutic areas. All six operate as one accountable system inside client-controlled environments, with scope, ownership, and decision boundaries visible from the start.
CAPABILITIES CATALOG
CAPABILITIES CATALOG
01
01
ALL THERAPEUTIC AREAS
ALL THERAPEUTIC AREAS
Protocol-driven coverage analysis, sponsor budget analysis, CTA and SOW review, CTMS study build, and amendment budget impact.
Protocol-driven coverage analysis, sponsor budget analysis, CTA and SOW review, CTMS study build, and amendment budget impact.
EXPLORE FINANCE
EXPLORE FINANCE
→
→
02
02
ALL THERAPEUTIC AREAS
ALL THERAPEUTIC AREAS
Registration, results reporting, record maintenance, quality-control remediation, disclosure calendars, and portfolio review.
Registration, results reporting, record maintenance, quality-control remediation, disclosure calendars, and portfolio review.
EXPLORE DISCLOSURE
EXPLORE DISCLOSURE
→
→
03
03
HEM/ONC
HEM/ONC
Controlled site-level execution, milestone visibility, specimen pathways, issue management, and close-out support.
Controlled site-level execution, milestone visibility, specimen pathways, issue management, and close-out support.
EXPLORE TRIAL OPERATIONS
EXPLORE TRIAL OPERATIONS
→
→
04
04
HEM/ONC
HEM/ONC
Ethical recruitment planning and retention support designed around appropriate oncology populations and minimal site burden.
Ethical recruitment planning and retention support designed around appropriate oncology populations and minimal site burden.
EXPLORE RECRUITMENT
EXPLORE RECRUITMENT
→
→
05
05
HEM/ONC
HEM/ONC
Feasibility through activation, with documentation, ownership, dependencies, and readiness made visible.
Feasibility through activation, with documentation, ownership, dependencies, and readiness made visible.
EXPLORE START UP
EXPLORE START UP
→
→
06
06
HEM/ONC
HEM/ONC
EDC and case-report-form support, query management, lab-value tracking, result reconciliation, and controlled data workflows.
EDC and case-report-form support, query management, lab-value tracking, result reconciliation, and controlled data workflows.
EXPLORE DATA MANAGEMENT
EXPLORE DATA MANAGEMENT
→
→
INDUSTRY MODEL
INDUSTRY MODEL
THE INDUSTRY DEFAULT
THE INDUSTRY DEFAULT
Here’s the truth nobody in this industry says out loud: the second the ink dries at a big CRO, your trial stops being their priority. You’ve felt it. Everyone’s felt it. So we engineered the exact opposite. The people who promise it are the people who deliver it, contractually. Senior attention is capped, protected, in writing. One therapeutic area. Zero tourists. Your trial gets the obsession it deserves, from pitch to database lock.
Here’s the truth nobody in this industry says out loud: the second the ink dries at a big CRO, your trial stops being their priority. You’ve felt it. Everyone’s felt it. So we engineered the exact opposite. The people who promise it are the people who deliver it, contractually. Senior attention is capped, protected, in writing. One therapeutic area. Zero tourists. Your trial gets the obsession it deserves, from pitch to database lock.
Here’s the truth nobody in this industry says out loud: the second the ink dries at a big CRO, your trial stops being their priority. You’ve felt it. Everyone’s felt it. So we engineered the exact opposite. The people who promise it are the people who deliver it, contractually. Senior attention is capped, protected, in writing. One therapeutic area. Zero tourists. Your trial gets the obsession it deserves, from pitch to database lock.
THE MODEL, INVERTED
THE MODEL, INVERTED
KARAMATA™
KARAMATA™
SENIOR ATTENTION
SENIOR ATTENTION
Capped and protected, in writing.
Capped and protected, in writing.
Capped and protected, in writing.
THERAPEUTIC AREA
THERAPEUTIC AREA
Hematology and oncology only. Zero tourists.
Hematology and oncology only. Zero tourists.
Hematology and oncology only. Zero tourists.
YOUR TRIAL
YOUR TRIAL
The priority, from pitch to database lock.
The priority, from pitch to database lock.
The priority, from pitch to database lock.
Visible responsibility begins with defined scope, named ownership, approved inputs, controlled outputs, and a clear decision boundary. KARAMATA prepares and enters. Clients determine, approve, release, and retain authority.
Visible responsibility begins with defined scope, named ownership, approved inputs, controlled outputs, and a clear decision boundary. KARAMATA prepares and enters. Clients determine, approve, release, and retain authority.
Visible responsibility begins with defined scope, named ownership, approved inputs, controlled outputs, and a clear decision boundary. KARAMATA prepares and enters. Clients determine, approve, release, and retain authority.
DECISION BOUNDARY
DECISION BOUNDARY
KARAMATA PREPARES AND ENTERS
KARAMATA PREPARES AND ENTERS
Every engagement begins with scope, dependencies, and readiness made visible.
Every engagement begins with scope, dependencies, and readiness made visible.
Work is completed inside approved client environments, on client systems.
Work is completed inside approved client environments, on client systems.
Each handoff identifies the accountable owner, the required input, and the next decision.
Each handoff identifies the accountable owner, the required input, and the next decision.
THE CLIENT DETERMINES AND RELEASES
THE CLIENT DETERMINES AND RELEASES
Clients determine and approve; KARAMATA never carries decision authority.
Clients determine and approve; KARAMATA never carries decision authority.
Records and results are released by the client, from the client’s own accounts.
Records and results are released by the client, from the client’s own accounts.
Authority remains explicit from the first record to the final release.
Authority remains explicit from the first record to the final release.
PATIENT RECRUITMENT & RETENTION
PATIENT RECRUITMENT & RETENTION
5to95™ Patient Recruitment & Retention helps sponsors and sites turn fragmented outreach, screening, enrollment, and follow-up into a coordinated path to participation—reaching beyond the few patients already within the clinical-trial system to the many who remain outside it.
5to95™ Patient Recruitment & Retention helps sponsors and sites turn fragmented outreach, screening, enrollment, and follow-up into a coordinated path to participation—reaching beyond the few patients already within the clinical-trial system to the many who remain outside it.
5to95™ Patient Recruitment & Retention helps sponsors and sites turn fragmented outreach, screening, enrollment, and follow-up into a coordinated path to participation—reaching beyond the few patients already within the clinical-trial system to the many who remain outside it.
5to95™—because moving from the historical 5% estimate to 7.1% two decades later isn’t exactly champagne-worthy.
5to95™—because moving from the historical 5% estimate to 7.1% two decades later isn’t exactly champagne-worthy.
Tell us where complexity is slowing the work. We’ll help make the scope, ownership, and next decision visible.
Tell us where complexity is slowing the work. We’ll help make the scope, ownership, and next decision visible.
Tell us where complexity is slowing the work. We’ll help make the scope, ownership, and next decision visible.
